The authors provided new insights into the mechanisms that underlied Dyrk1b-induced hepatic lipogenesis and hepatic insulin resistance and identified Dyrk1b as a therapeutic target for non-alcoholic liver steatohepatitis and insulin resistance in the liver.
[Journal of Clinical Investigation]
7992332
{7992332:EEEEEEEE}
apa
50
1
169658
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/